76
Participants
Start Date
July 31, 2011
Primary Completion Date
April 30, 2013
Study Completion Date
March 31, 2014
ALD518
IV
0.9% saline
IV Infusion
Hanusch Krankenhaus, Vienna
St. Vincent's Hospital, Darlinghurst
Calvary Mater Newcastle, Waratah
Royale Brisbane and Women's Hospital, Herston
Univ. Klinik fur Innere Medizin III, Salzburg
Adelaide Radiotherapy Centre, Adelaide
Mount Sinai School of Medicine, New York
SUNY Upstate Medical University, Syracuse
Temple University Hospital, Philadelphia
A.O. San Paolo - Polo Universitario, Milan
Spartanburg Regional Medical Center, Spartanburg
Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine
Morton Plant Mease Health Care, Clearwater
Karmanos Cancer Center, Detroit
Detroit Clinical Research Center, Farmington Hills
Uniklinik Koln, Cologne
University Medical School, Saarland, Homburg
University of Texas Southwestern Medical Center, Dallas
Cancer Specialists of Southern Texas, Corpus Christi
Universitatsklinikum Freiburg, Freiburg im Breisgau
University of New Mexico Cancer Center, Albuquerque
VA Puget Sound Health Care Syatem, Seattle
Dana Farber Cancer Institute, Boston
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Princess Alexandra Hospital, Woolloongabba
Royal Adelaide Hospital, Adelaide
LKH Graz, HNO Ambulanz, Graz
Istituto Nazionale dei tumari, Milan
Cancer Centre of Southeastern Ontario, Kingston
Maisonneuve-Rosemont Hospital, Montreal
CHUQ-L'Hotel-Dieu de Quebec, Québec
Lead Sponsor
CSL Behring
INDUSTRY